TAHL CINDY
Known title: General Counsel and SecretaryCIK: 0001655472
Associated companies
Transaction History
| FATE | ▼ Sell | Open Market | 38,800 | $95K | 8/4/2026 | View on chart |
| FATE | ▼ Sell | Open Market | 25,590 | $48K | 5/20/2026 | View on chart |
| FATE | ▲ Buy | Option Exercise | 122,220 | $161K | 5/6/2026 | View on chart |
| FATE | ▲ Buy | Option Exercise | 44,444 | $47K | 5/6/2026 | View on chart |
| FATE | ▲ Buy | Grant | 100,000 | $0 | 1/15/2026 | View on chart |
| FATE | ▼ Sell | Open Market | 10,589 | $11K | 1/9/2026 | View on chart |
| FATE | ▼ Sell | Open Market | 9,037 | $10K | 8/4/2025 | View on chart |
| FATE | ▲ Buy | Grant | 70,000 | $0 | 1/15/2025 | View on chart |
| FATE | ▼ Sell | Open Market | 5,654 | $9K | 1/10/2025 | View on chart |
| FATE | ▲ Buy | Grant | 200,000 | $0 | 7/29/2024 | View on chart |
| FATE | ▼ Sell | Open Market | 10,874 | $48K | 1/9/2024 | View on chart |
| FATE | ▼ Sell | Open Market | 24,363 | $58K | 11/9/2023 | View on chart |
| FATE | ▼ Sell | Open Market | 11,553 | $61K | 1/10/2023 | View on chart |
| FATE | ▲ Buy | Option Exercise | 25,000 | $164K | 6/1/2022 | View on chart |
| FATE | ▼ Sell | Open Market | 25,000 | $574K | 6/1/2022 | View on chart |
| FATE | ▲ Buy | Option Exercise | 5,567 | $36K | 4/1/2022 | View on chart |
| FATE | ▼ Sell | Open Market | 25,000 | $971K | 4/1/2022 | View on chart |
| FATE | ▲ Buy | Option Exercise | 19,433 | $94K | 4/1/2022 | View on chart |
| FATE | ▲ Buy | Grant | 33,302 | $0 | 1/25/2022 | View on chart |
| FATE | ▼ Sell | Open Market | 4,883 | $237K | 1/11/2022 | View on chart |
| FATE | ▼ Sell | Open Market | 536 | $26K | 1/11/2022 | View on chart |
| FATE | ▼ Sell | Open Market | 7,095 | $329K | 1/10/2022 | View on chart |
| FATE | ▼ Sell | Open Market | 643 | $30K | 1/10/2022 | View on chart |
| FATE | ▲ Buy | Option Exercise | 50,000 | $328K | 1/3/2022 | View on chart |
| FATE | ▼ Sell | Open Market | 4,427 | $256K | 1/3/2022 | View on chart |
| FATE | ▼ Sell | Open Market | 16,900 | $994K | 1/3/2022 | View on chart |
| FATE | ▼ Sell | Open Market | 27,812 | $1.7M | 1/3/2022 | View on chart |
| FATE | ▼ Sell | Open Market | 861 | $52K | 1/3/2022 | View on chart |
| FATE | ▲ Buy | Grant | 60,958 | $0 | 11/19/2021 | View on chart |
| FATE | ▲ Buy | Option Exercise | 50,000 | $328K | 10/1/2021 | View on chart |
| FATE | ▼ Sell | Open Market | 16,312 | $947K | 10/1/2021 | View on chart |
| FATE | ▼ Sell | Open Market | 21,844 | $1.3M | 10/1/2021 | View on chart |
| FATE | ▼ Sell | Open Market | 11,844 | $707K | 10/1/2021 | View on chart |
AI Market Commentary
AI-generatedAll commentary →Synthesized from recent news and fundamentals/technical data -- not human analyst commentary or trader sentiment.
September 27, 2026
Fate Therapeutics Secures $15M CIRM Grant for Lupus Trial
Fate Therapeutics announced it received a $15 million grant from the California Institute for Regenerative Medicine to advance its Phase 2 RECLAIM-LN trial for lupus nephritis. This funding supports the development of the company's FT819 therapy. The news coincides with the stock trading near its 52-week low, providing a potential catalyst for the healthcare sector.
Fate Therapeutics Secures $15M CIRM Grant for Lupus Trial. Fate Therapeutics announced it received a $15 million grant from the California Institute for Regenerative Medicine to advance its Phase 2 RECLAIM-LN trial for lupus nephritis. This funding supports the development of the company's FT819 therapy. The news coincides with the stock trading near its 52-week low, providing a potential catalyst for the healthcare sector.